Literature DB >> 23844648

Two-hour insulinemia after oral glucose overload and women at risk of pregnancy-induced hypertensive disorders.

José Romero1, Eduardo Spinedi.   

Abstract

OBJECTIVE: Pregnant women with impaired insulin sensitivity are at risk for developing pregnancy-induced hypertensive disorders (PIHD). We analyzed glucose and insulin circulating levels throughout a 2-h oral 75 g glucose tolerance test in pregnant women, and related the 2-h insulinemias to PIHD prevalence.
METHODS: Pregnant women (gestational week 24-28) were submitted to a glucose overload, and glucose and insulin plasma concentrations were measured throughout the test. These peripheral metabolite levels, the homeostasis model assessment (HOMA) values and the glucose to insulin ratio (G:Ir) were analyzed. Anthropometric parameters and pregnancy outcome were recorded.
RESULTS: Women with normal fasting glycemia, insulinemia and HOMA values, G:Ir and 2 h-glycemia but whose 2 h-insulinemia was higher than 215.25 pM were at greater risk for developing late pregnancy hypertension and preeclampsia compared to women of similar characteristics but whose 2 h-insulinemias were lower than 215.25 pM.
CONCLUSION: 2-h insulinemias higher than 215.25 pM after a 75 g glucose overload could be highly indicative of women at increased risk of developing PIHD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23844648     DOI: 10.3109/10641955.2013.807821

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  2 in total

1.  Clinical study on the association between pregnancy-induced hypertension and insulin resistance.

Authors:  Zhifang Chen; Weiling Liu; Xiaoqin Sun; Lingling Zhu
Journal:  Exp Ther Med       Date:  2017-03-02       Impact factor: 2.447

2.  Estimating rate of insulin resistance in patients with preeclampsia using HOMA-IR index and comparison with nonpreeclampsia pregnant women.

Authors:  Farideh Rezaei Abhari; Maryam Ghanbari Andarieh; Asadollah Farokhfar; Soleiman Ahmady
Journal:  Biomed Res Int       Date:  2014-04-09       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.